Clinical Trials Articles
A clinical trial comparing the protective efficacy in older adults of a quadrivalent recombinant influenza vaccine with a standard-dose, egg-grown quadrivalent inactivated influenza vaccine during the A/H3N2-predominant 2014-2015 influenza season showed RIV4 provided better protection against confirmed influenza-like illness among older adults.
Results of a Phase II clinical trial ofPfizer’s preventive vaccine againstClostridium difficile (C. diff) showed the vaccine was safe and stimulated a C. diff targeted immune response.
A PhaseI/II study of nine patients with hemophilia B who underwent Spark Therapeutics’ SPK-9001 gene therapy are promising, despite two adverse autoimmune reactions.
A Phase I/II study indicates that haplo identical hematopoietic stem cell transplantation (haplo-HSCT), after depletion of α/β T cells and B cells followed by adoptive infusion of donorBPX-501 cells, is an effective alternative for children with primary immunodeficiency disease (PI) in need of an urgent allograft or lacking a suitable human leukocyte antigen (HLA)-matched donor.
Results from the Phase III PROLONG9FP ongoing extension clinical development program evaluating the long-term efficacy and safety of IDELVION (coagulation factor IX [recombinant], albumin fusion protein) showed that extended prophylaxis treatment regimens effectively prevented bleeds while also reducing overall IDELVION consumption.
